Lilly Gets Its Wish: STAR Results Show Evista Reduces Breast Cancer Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Trial shows Lilly’s Evista reduces risk of developing invasive breast cancer by 50%, comparable to AstraZeneca’s Nolvadex.
You may also be interested in...
Lilly Will Add 40% Capacity To Diabetes Sales Force In Q1
Firm also announces the submission of an sNDA for Evista for breast cancer risk reduction.
Lilly Will Add 40% Capacity To Diabetes Sales Force In Q1
Firm also announces the submission of an sNDA for Evista for breast cancer risk reduction.
Lilly's Evista Not Effective For Heart Disease, Preliminary Results Show
Company plans to submit an sNDA for raloxifene to treat invasive breast cancer by the end of 2006.